Mcam 7.5Mg
-550x550.png "Mcam 7.5Mg - 000512 - www.mycare.lk")
Mcam 7.5Mg
- Stock: Out Of Stock
- Model: Mcam 7.5Mg
- Pack Size: 200
- SKU: 000512
- Pack size: 200
- Generic name: Meloxicam
COMPOSITION
M-Cam7.5 Each uncoated tablet contains Meloxicam BP 7.5mg. M-Cam 15 Each uncoated tablet contains 15mg. Excipients Sodium Citrate, Lactose, Microcrystalline Cellulose, Crospovidone, Magnesium Stearate & Colloidal Anhydrous Silica.
WARNING
Cardiovascular Risk: NSAIDS may cause an increased risk of serious cardiovascular thrombotic events. myocardial infarction. and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Meloxicam is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. Gastrointestinal Risk: NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration; and perforation of the stomach or intestines. which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.
DESCRIPTION
Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAlDs). Meloxicam is chemically designated as 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1, 2-benzothiazine-3-carboxamide-1, 1-dioxide. The molecular weight is 351.4.
CONTRAINDICATIONS
M-Cam contraindicated in patients with known hypersensitivity to meloxicam. M-Cam should not be given to patients who have experienced asthma, urticaria, or allergic type reactions after taking aspirin or other NSAlDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients. M-Cam is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
OVERDOSAGE
There is limited experience with meloxicam overdose. Four cases have taken 6 to 11 times the highest recommended dose; ail recovered. Cholestyramine is known to accelerate the clearance of meloxicam. Symptoms following acute NSAID overdose are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleedings can occur. Severe poisoning may result in hypertension, acute renal failure, hepatic dysfunction. respiratory depression. coma. convulsions, cardiovascular collapse and cardiac arrest. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDS. and may occur following an overdose. Patients should be managed with symptomatic and supportive care following an NSAID overdose. In cases of acute overdose, gastric lavage followed by activated charcoal is recommended. Gastric lavage performed more than one hour after overdose has little benefit in the treatment of overdose. Administration of activated charcoal is recommended for patients who present 1-2 hours after overdose. For substantial overdose or severely symptomatic patients, activated charcoal may be administered repeatedly. Accelerated removal of meloxicam by 4 gm oral doses of cholestyramine given three times a day was demonstrated in a clinical trial. Administration of cholestyramine may be useful following an overdose. Forced diuresis, alkalization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.
UNICHEM LABORATORIES LTD
-250x250.png "M-Cam 7.5Mg")
